Soligenix Anti-Tumor Therapy Demonstrates Positive Efficacy
Armed with supportive data from Phase II and III trials, share price showing strength and Company to pursue partnership opportunities for novel molecule
Soligenix, Inc. (Nasdaq: SNGX) has demonstrated positive efficacy of dusquetide as an anti-tumor therapy in non-clinical animal studies. Previously published studies have also confirmed dusquetide’s efficacy in treating:
- Breast cancer: As a stand-alone and combination anti-tumor therapy with radiation, chemotherapy and targeted therapy (MCF-7 breast cancer cell line)
- Severe Oral Mucositis (SOM): Reduces the duration of SOM with the potential ancillary benefit of an acceleration in the clearance of tumor response and an increase in overall survival in patients receiving chemo-radiation for head and neck cancer.
- And may have applications in treating other indications including multiple myeloma, liver cancer, lung cancer, intestinal cancer, colorectal cancer and ovarian cancer.
Dusquetide is a novel synthetic peptide that modulates the body’s innate immune system, including the response to tumors and the response of the tumors themselves. A review of the potential action of dusquetide is available here. Soligenix will pursue potential product and partnership opportunities for this novel molecule.
SNGX share price reacted favorably to this news, with a price increase of over 5% on the day, with nearly 10 times average volume.